董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anne M. Phillips | 女 | Director | 70 | 7.21万美元 | 未持股 | 2020-03-12 |
| Barbara Yanni | 女 | Director | 69 | 8.11万美元 | 未持股 | 2020-03-12 |
| Julie H. McHugh | 女 | Director | 59 | 7.31万美元 | 未持股 | 2020-03-12 |
| Carrie L. Bourdow | 女 | President, Chief Executive Officer and Director | 57 | 未披露 | 未持股 | 2020-03-12 |
| Leon O. Moulder, Jr | -- | Chairman, Board of Director | -- | 未披露 | 未持股 | 2020-03-12 |
| Scott Braunstein | -- | Director | -- | 未披露 | 未持股 | 2020-03-12 |
| Michael R. Dougherty | 男 | Director | 66 | 8.11万美元 | 未持股 | 2020-03-12 |
| Jake R. Nunn | 男 | Director | 53 | 6.96万美元 | 未持股 | 2020-03-12 |
| Leon O. Moulder, Jr. | 男 | Chairman, Board of Director | 67 | 10.11万美元 | 未持股 | 2020-03-12 |
| Maxine Gowen | 女 | Director | 66 | 208.53万美元 | 未持股 | 2020-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carrie L. Bourdow | 女 | President, Chief Executive Officer and Director | 57 | 未披露 | 未持股 | 2020-03-12 |
| Mark A Demitrack | 男 | Senior Vice President and Chief Medical Officer | 62 | 未披露 | 未持股 | 2020-03-12 |
| Robert T. Yoder | 男 | Senior Vice President and Chief Business Officer | 54 | 未披露 | 未持股 | 2020-03-12 |
| Barry Shin | 男 | Senior Vice President and Chief Financial Officer | 48 | 未披露 | 未持股 | 2020-03-12 |
| Scott Applebaum | -- | Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs | 53 | 未披露 | 未持股 | 2020-03-12 |
董事简历
中英对照 | 中文 | 英文- Anne M. Phillips
-
Anne M. Phillips，曾担任Carmot Therapeutics Inc.的成员。自2022年11月起担任董事会成员。从2013年到2022年8月，她曾担任Novo Nordisk Inc.（一家制药公司）的临床开发、医疗和法规事务高级副总裁，在那里她于2011年加入Novo Nordisk，担任临床医疗法规公司副总裁。从1998年到2010年，她担任生物制药公司GlaxoSmithKline plc的各种副总裁职位，包括临床开发副总裁。从1992年到1998年，她担任Wellesley Central Hospital/St. St。的传染病项目负责人和副首席医师。多伦多的迈克尔医院。自2014年和2021年2月，她分别担任上市生物制药公司Trevena, Inc.和Vaccitech plc的董事会成员。她自2021年起担任Trevena Inc.薪酬委员会主席，并于2014年至2021年担任其薪酬委员会成员。她还担任Trevena, Inc.的提名和公司治理委员会成员（2014年以来），以及Vaccitech plc的薪酬委员会主席（2022年以来）。从2019年4月到2020年10月，她担任AMAG Pharmaceuticals, Inc.（一家上市制药公司，直到被Covis Pharma收购）的董事会成员。她在多伦多大学获得医学博士学位，在西部大学获得动物学学士学位。
Anne M. Phillips,has served as a member of Carmot Therapeutics Inc. Board of Directors since November 2022. From 2013 to August 2022, Dr. Phillips has served as Senior Vice President, Clinical Development, Medical & Regulatory Affairs at Novo Nordisk Inc., a pharmaceutical company, where she joined as a Corporate Vice President of Clinical Medical Regulatory Novo Nordisk in 2011. From 1998 to 2010 Dr. Phillips held various Vice President positions at the biopharmaceutical company, GlaxoSmithKline plc, including Vice President of Clinical Development. From 1992 to 1998, Dr. Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael's Hospital in Toronto. Dr. Phillips has served on the board of publicly traded biopharmaceutical companies Trevena, Inc. and Vaccitech plc since 2014 and February 2021, respectively. Dr. Phillips has been the Chair of the compensation committee of Trevena Inc. since 2021 and was a member of its compensation committee from 2014 to 2021. She has also served as a member of Trevena, Inc.'s nominating and corporate governance committee since 2014 and Chair of Vaccitech plc's compensation committee since 2022. From April 2019 to October 2020, Dr. Phillips served on the board of directors of AMAG Pharmaceuticals, Inc., a publicly traded pharmaceutical company until it was acquired by Covis Pharma. She received an M.D. from the University of Toronto and a B.S. in Zoology from Western University. - Anne M. Phillips，曾担任Carmot Therapeutics Inc.的成员。自2022年11月起担任董事会成员。从2013年到2022年8月，她曾担任Novo Nordisk Inc.（一家制药公司）的临床开发、医疗和法规事务高级副总裁，在那里她于2011年加入Novo Nordisk，担任临床医疗法规公司副总裁。从1998年到2010年，她担任生物制药公司GlaxoSmithKline plc的各种副总裁职位，包括临床开发副总裁。从1992年到1998年，她担任Wellesley Central Hospital/St. St。的传染病项目负责人和副首席医师。多伦多的迈克尔医院。自2014年和2021年2月，她分别担任上市生物制药公司Trevena, Inc.和Vaccitech plc的董事会成员。她自2021年起担任Trevena Inc.薪酬委员会主席，并于2014年至2021年担任其薪酬委员会成员。她还担任Trevena, Inc.的提名和公司治理委员会成员（2014年以来），以及Vaccitech plc的薪酬委员会主席（2022年以来）。从2019年4月到2020年10月，她担任AMAG Pharmaceuticals, Inc.（一家上市制药公司，直到被Covis Pharma收购）的董事会成员。她在多伦多大学获得医学博士学位，在西部大学获得动物学学士学位。
- Anne M. Phillips,has served as a member of Carmot Therapeutics Inc. Board of Directors since November 2022. From 2013 to August 2022, Dr. Phillips has served as Senior Vice President, Clinical Development, Medical & Regulatory Affairs at Novo Nordisk Inc., a pharmaceutical company, where she joined as a Corporate Vice President of Clinical Medical Regulatory Novo Nordisk in 2011. From 1998 to 2010 Dr. Phillips held various Vice President positions at the biopharmaceutical company, GlaxoSmithKline plc, including Vice President of Clinical Development. From 1992 to 1998, Dr. Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael's Hospital in Toronto. Dr. Phillips has served on the board of publicly traded biopharmaceutical companies Trevena, Inc. and Vaccitech plc since 2014 and February 2021, respectively. Dr. Phillips has been the Chair of the compensation committee of Trevena Inc. since 2021 and was a member of its compensation committee from 2014 to 2021. She has also served as a member of Trevena, Inc.'s nominating and corporate governance committee since 2014 and Chair of Vaccitech plc's compensation committee since 2022. From April 2019 to October 2020, Dr. Phillips served on the board of directors of AMAG Pharmaceuticals, Inc., a publicly traded pharmaceutical company until it was acquired by Covis Pharma. She received an M.D. from the University of Toronto and a B.S. in Zoology from Western University.
- Barbara Yanni
-
Barbara Yanni（2001年11月-2014年3月退休）担任Merck & Co（一家制药公司）副总裁和首席授权官。在这之前，她在Merck担任不同的职位，包括企业发展、财务评价、税收。她也在Symic Biomedical股份有限公司（Symic Biomedical, Inc，一家私人生物技术公司）董事会工作。她拥有斯坦福大学法学院（Stanford Law School）博士学位和韦尔斯利学院（Wellesley College）学士学位。她也拥有纽约大学（New York University）税收法律硕士学位。
Barbara Yanni has served as a director since December 2020. Ms. Yanni was Vice President and Chief Licensing Officer at Merck & Co. MRK, a pharmaceutical company, from November 2001 until her retirement in March 2014. Prior to this, Ms. Yanni served in various roles at Merck including in corporate development, financial evaluation, and tax. Ms. Yanni currently serves on the board of directors of two public biotechnology companies: Trevena, Inc. and Vaccinex, Inc. Ms. Yanni is also a member of the board of directors of Mesentech, Inc., a private Canadian biotechnology company. Ms. Yanni earned a J.D. from Stanford Law School and an A.B. from Wellesley College. She also holds a Masters of Law in Taxation from New York University. Before joining Merck in 1985 Barbara was a tax lawyer in New York City. - Barbara Yanni（2001年11月-2014年3月退休）担任Merck & Co（一家制药公司）副总裁和首席授权官。在这之前，她在Merck担任不同的职位，包括企业发展、财务评价、税收。她也在Symic Biomedical股份有限公司（Symic Biomedical, Inc，一家私人生物技术公司）董事会工作。她拥有斯坦福大学法学院（Stanford Law School）博士学位和韦尔斯利学院（Wellesley College）学士学位。她也拥有纽约大学（New York University）税收法律硕士学位。
- Barbara Yanni has served as a director since December 2020. Ms. Yanni was Vice President and Chief Licensing Officer at Merck & Co. MRK, a pharmaceutical company, from November 2001 until her retirement in March 2014. Prior to this, Ms. Yanni served in various roles at Merck including in corporate development, financial evaluation, and tax. Ms. Yanni currently serves on the board of directors of two public biotechnology companies: Trevena, Inc. and Vaccinex, Inc. Ms. Yanni is also a member of the board of directors of Mesentech, Inc., a private Canadian biotechnology company. Ms. Yanni earned a J.D. from Stanford Law School and an A.B. from Wellesley College. She also holds a Masters of Law in Taxation from New York University. Before joining Merck in 1985 Barbara was a tax lawyer in New York City.
- Julie H. McHugh
-
Julie H. McHugh，2010年3月至2013年5月，担任Endo Health Solutions, Inc.的首席运营官，负责专有药和仿制药业务。加入Endo之前，2009年4月至12月，她担任Nora Therapeutics, Inc.的首席执行官，这是一个风投背景公司，从事开发用于治疗不孕不育疾病的新疗法；2006-2008，担任Johnson & Johnson全球病毒业务部的主席；此前，她是该企业子公司Centocor, Inc.的总裁。任职于Johnson & Johnson期间，她曾负责并推动了一些产品的上市，包括Remicade英夫利昔单抗、Prezista（达芦那韦）、Intelence（依曲韦林）。她现为：Smeal College of Business of the Pennsylvania State University的监事，2个上市公司Ironwood Pharmaceuticals, Inc. 、Trevena Pharmaceuticals, Inc.，以及私营企业Xellia Pharmaceuticals, Inc.的董事；她还是Trevena Pharmaceuticals的提名与治理委员会成员、Xellia Pharmaceuticals的商业委员会成员、Ironwood Pharmaceuticals, Inc.的审计委员会成员。2011年1月至2013年1月，她曾担任上市企业ViroPharma Inc.的董事；也曾任职于Biotechnology Industry Organization （BIO）、the Pennsylvania Biotechnology Association 、the New England Healthcare Institute （NEHI）的董事。她在St. Joseph's University获得工商管理硕士学位，在Pennsylvania State University获得学士学位。
Julie H. McHugh has served as a member of Lantheus Holdings, Inc. Board since June 2015. Ms. McHugh served as Chief Operating Officer of Endo Health Solutions, Inc. from March 2010 until her retirement in May 2013 where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to this, Ms. McHugh was Chief Executive Officer of Nora Therapeutics, Inc., a venture capital backed biotech start-up company focused on developing novel therapies for the treatment of infertility disorders. Previously, Ms. McHugh served as Company Group Chairman for Johnson & Johnson's worldwide virology business unit, and prior to this, she was President of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw the development and launches of several products, including Remicade infliximab, Prezista (darunavir) and Intelence (etravirine). Prior to joining Centocor, Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc. Ms. McHugh currently serves as chair of the board of directors of Ironwood Pharmaceuticals, Inc. and member of the board of directors of Lantheus Holdings, Inc., New Xellia Group A/S, and Trevena Pharmaceuticals, Inc. Ms. McHugh previously served on the board of directors of the Biotechnology Industry Organization (BIO), the New England Healthcare Institute (NEHI), the Pennsylvania Biotechnology Association, EPIRUS Biopharmaceuticals, Inc. and ViroPharma Inc. Ms. McHugh received her M.B.A. from St. Joseph's University and her B.S. from Pennsylvania State University. - Julie H. McHugh，2010年3月至2013年5月，担任Endo Health Solutions, Inc.的首席运营官，负责专有药和仿制药业务。加入Endo之前，2009年4月至12月，她担任Nora Therapeutics, Inc.的首席执行官，这是一个风投背景公司，从事开发用于治疗不孕不育疾病的新疗法；2006-2008，担任Johnson & Johnson全球病毒业务部的主席；此前，她是该企业子公司Centocor, Inc.的总裁。任职于Johnson & Johnson期间，她曾负责并推动了一些产品的上市，包括Remicade英夫利昔单抗、Prezista（达芦那韦）、Intelence（依曲韦林）。她现为：Smeal College of Business of the Pennsylvania State University的监事，2个上市公司Ironwood Pharmaceuticals, Inc. 、Trevena Pharmaceuticals, Inc.，以及私营企业Xellia Pharmaceuticals, Inc.的董事；她还是Trevena Pharmaceuticals的提名与治理委员会成员、Xellia Pharmaceuticals的商业委员会成员、Ironwood Pharmaceuticals, Inc.的审计委员会成员。2011年1月至2013年1月，她曾担任上市企业ViroPharma Inc.的董事；也曾任职于Biotechnology Industry Organization （BIO）、the Pennsylvania Biotechnology Association 、the New England Healthcare Institute （NEHI）的董事。她在St. Joseph's University获得工商管理硕士学位，在Pennsylvania State University获得学士学位。
- Julie H. McHugh has served as a member of Lantheus Holdings, Inc. Board since June 2015. Ms. McHugh served as Chief Operating Officer of Endo Health Solutions, Inc. from March 2010 until her retirement in May 2013 where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to this, Ms. McHugh was Chief Executive Officer of Nora Therapeutics, Inc., a venture capital backed biotech start-up company focused on developing novel therapies for the treatment of infertility disorders. Previously, Ms. McHugh served as Company Group Chairman for Johnson & Johnson's worldwide virology business unit, and prior to this, she was President of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw the development and launches of several products, including Remicade infliximab, Prezista (darunavir) and Intelence (etravirine). Prior to joining Centocor, Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc. Ms. McHugh currently serves as chair of the board of directors of Ironwood Pharmaceuticals, Inc. and member of the board of directors of Lantheus Holdings, Inc., New Xellia Group A/S, and Trevena Pharmaceuticals, Inc. Ms. McHugh previously served on the board of directors of the Biotechnology Industry Organization (BIO), the New England Healthcare Institute (NEHI), the Pennsylvania Biotechnology Association, EPIRUS Biopharmaceuticals, Inc. and ViroPharma Inc. Ms. McHugh received her M.B.A. from St. Joseph's University and her B.S. from Pennsylvania State University.
- Carrie L. Bourdow
-
Carrie L. Bourdow自2015年5月起担任公司高级副总裁兼首席商务官。2013年5月至2015年5月，她在Cubist Pharmaceuticals, Inc.担任营销副总裁。2013年加入Cubist之前，Bourdow女士在Merck & Co., Inc.任职20多年，在那里她在多个治疗领域担任越来越重要的职务，包括抗感染、急性心脏衰竭和疼痛。 Bourdow女士获得了Hendrix College的学士学位和 Southern Illinois University的工商管理硕士学位。
Carrie L. Bourdow has served as a member of our Board since February 2020. Ms. Bourdow has served as the President, Chief Executive Officer and a member of the board of directors of Trevena, Inc. Nasdaq: TRVN since October 2018. Prior to her role as Chief Executive Officer, Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from May 2013 until its acquisition by Merck & Co., Inc. in May 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for products totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across commercial functions and therapeutic areas. Since June 2017 she has served on the board of directors of Nabriva Therapeutics plc. (Nasdaq: NBRV), a publicly traded biopharmaceutical company. - Carrie L. Bourdow自2015年5月起担任公司高级副总裁兼首席商务官。2013年5月至2015年5月，她在Cubist Pharmaceuticals, Inc.担任营销副总裁。2013年加入Cubist之前，Bourdow女士在Merck & Co., Inc.任职20多年，在那里她在多个治疗领域担任越来越重要的职务，包括抗感染、急性心脏衰竭和疼痛。 Bourdow女士获得了Hendrix College的学士学位和 Southern Illinois University的工商管理硕士学位。
- Carrie L. Bourdow has served as a member of our Board since February 2020. Ms. Bourdow has served as the President, Chief Executive Officer and a member of the board of directors of Trevena, Inc. Nasdaq: TRVN since October 2018. Prior to her role as Chief Executive Officer, Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from May 2013 until its acquisition by Merck & Co., Inc. in May 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for products totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across commercial functions and therapeutic areas. Since June 2017 she has served on the board of directors of Nabriva Therapeutics plc. (Nasdaq: NBRV), a publicly traded biopharmaceutical company.
- Leon O. Moulder, Jr
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Scott Braunstein
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Michael R. Dougherty
-
Michael R. Dougherty，他曾一直担任公司董事（2013年5月以来）。从2012年5月到2012年10月，他曾担任Kalidex Pharmaceuticals公司的首席执行官兼董事会成员。他曾担任Adolor公司的总裁兼首席执行官、董事（从2006年12月到2011年12月）。他于2002年11月加入Adolor公司，担任负责商业运营的高级副总裁，并被任命为总裁兼首席执行官，也曾担任多种职务，包括首席运营官兼首席财务官。从2000年11月到2002年11月，他担任Genomics Collaborative公司（一家民营功能基因组学公司）的总裁兼首席运营官。此前，他曾担任Genaera Corporation（一个上市的生物技术公司）的多种高级职务，包括总裁兼首席执行官，也曾担任Centocor公司（上市的生物技术公司）的多种高级职务，包括高级副总裁兼首席财务官。他目前担任Cempra公司（上市公司）、Celator Pharmaceuticals公司（上市公司）、Trevena公司的董事。他也曾担任Viropharma Incorporated公司的董事（从2004年到2014年1月）。他获得Villanova University的经济学学士学位。他广泛了解生物技术产业的关键问题，包括金融、研发、销售和营销、策略和操作，也拥有担任几家生物技术公司的首席执行官的管理经验，因此他应该服务于公司的董事会。
Michael R. Dougherty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2019, and as chair of Idera Pharmaceuticals, Inc. Board of Directors from 2021 until 2022. Mr. Dougherty currently serves on the board of directors of Trevena, Inc. (Nasdaq: TRVN). Mr. Dougherty was executive chairman of Celator Pharmaceuticals, Inc., or Celator, from 2015 until its acquisition by Jazz Pharmaceuticals plc in 2016; he also served as a director of Celator from 2013 to 2016. Mr. Dougherty previously served in a variety of senior positions in the biopharmaceutical industry, including as CEO, President, Chief Operating Officer, and Chief Financial Officer. He also previously served as a member of the board of directors of and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), Foundation Medicine, Inc., Adolor Corporation, Genaera Corporation, Aviragen Therapeutics, Inc., Cempra, Inc., and ViroPharma Incorporated. Mr. Dougherty received a Bachelor of Science in Accounting from Villanova University. - Michael R. Dougherty，他曾一直担任公司董事（2013年5月以来）。从2012年5月到2012年10月，他曾担任Kalidex Pharmaceuticals公司的首席执行官兼董事会成员。他曾担任Adolor公司的总裁兼首席执行官、董事（从2006年12月到2011年12月）。他于2002年11月加入Adolor公司，担任负责商业运营的高级副总裁，并被任命为总裁兼首席执行官，也曾担任多种职务，包括首席运营官兼首席财务官。从2000年11月到2002年11月，他担任Genomics Collaborative公司（一家民营功能基因组学公司）的总裁兼首席运营官。此前，他曾担任Genaera Corporation（一个上市的生物技术公司）的多种高级职务，包括总裁兼首席执行官，也曾担任Centocor公司（上市的生物技术公司）的多种高级职务，包括高级副总裁兼首席财务官。他目前担任Cempra公司（上市公司）、Celator Pharmaceuticals公司（上市公司）、Trevena公司的董事。他也曾担任Viropharma Incorporated公司的董事（从2004年到2014年1月）。他获得Villanova University的经济学学士学位。他广泛了解生物技术产业的关键问题，包括金融、研发、销售和营销、策略和操作，也拥有担任几家生物技术公司的首席执行官的管理经验，因此他应该服务于公司的董事会。
- Michael R. Dougherty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2019, and as chair of Idera Pharmaceuticals, Inc. Board of Directors from 2021 until 2022. Mr. Dougherty currently serves on the board of directors of Trevena, Inc. (Nasdaq: TRVN). Mr. Dougherty was executive chairman of Celator Pharmaceuticals, Inc., or Celator, from 2015 until its acquisition by Jazz Pharmaceuticals plc in 2016; he also served as a director of Celator from 2013 to 2016. Mr. Dougherty previously served in a variety of senior positions in the biopharmaceutical industry, including as CEO, President, Chief Operating Officer, and Chief Financial Officer. He also previously served as a member of the board of directors of and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), Foundation Medicine, Inc., Adolor Corporation, Genaera Corporation, Aviragen Therapeutics, Inc., Cempra, Inc., and ViroPharma Incorporated. Mr. Dougherty received a Bachelor of Science in Accounting from Villanova University.
- Jake R. Nunn
-
Jake R. Nunn。自TPI和Novacea2009年1月完成合并，Nunn先生一直是我们董事会的成员，自2006年6月，Nunn先生一直是风险投资公司New Enterprise Associates, Inc.的合伙人，2001年1月至2006年6月，他是MPM BioEquities Fund的合伙人及分析师，这是MPM资本旗下的一家风险投资公司。Nunn先生拥有达特茅斯学院（Dartmouth College）学士学位，并拥有斯坦福大学研究生院（Stanford University Graduate School of Business）的经济学管理硕士学位。Nunn先生拥有特许金融分析师称号，是旧金山CFA协会的会员。Nunn先生也担任海波治疗（Hyperion Therapeutics），Trevena，和TriVascular技术公司（TriVascular Technologies，Inc）这些所有公开上市的生命科学公司的董事。
Jake R. Nunn has served on Regulus Therapeutics Inc. Board of Directors since June 2019. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Prior to joining NEA, he served as a partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons. Mr. Nunn has served on the board of directors of Trevena, Inc., a publicly-held biotechnology company focused on CNS since July 2013 and Addex Therapeutics Ltd., a publicly-held biopharmaceutical company focused on allosteric modulators for neurological disorders since June 2019 and Oventus Medical Ltd., a publicly-held medical device company since February 2020. Mr. Nunn served on the board of directors of Dermira, Inc., a publicly-held biopharmaceutical company focused on dermatology, from May 2011 until its acquisition by Eli Lilly and Company in February 2020. From 2009 to May 2015 Mr. Nunn served on the board of directors of Hyperion Therapeutics, Inc. and from 2008 to February 2016 Mr. Nunn served on the board of directors of TriVascular Technologies, Inc. Mr. Nunn received his A.B. in economics from Dartmouth College and his M.B.A. from the Stanford Graduate School of Business. He also holds the Chartered Financial Analyst designation and is a member of the CFA Society of San Francisco. - Jake R. Nunn。自TPI和Novacea2009年1月完成合并，Nunn先生一直是我们董事会的成员，自2006年6月，Nunn先生一直是风险投资公司New Enterprise Associates, Inc.的合伙人，2001年1月至2006年6月，他是MPM BioEquities Fund的合伙人及分析师，这是MPM资本旗下的一家风险投资公司。Nunn先生拥有达特茅斯学院（Dartmouth College）学士学位，并拥有斯坦福大学研究生院（Stanford University Graduate School of Business）的经济学管理硕士学位。Nunn先生拥有特许金融分析师称号，是旧金山CFA协会的会员。Nunn先生也担任海波治疗（Hyperion Therapeutics），Trevena，和TriVascular技术公司（TriVascular Technologies，Inc）这些所有公开上市的生命科学公司的董事。
- Jake R. Nunn has served on Regulus Therapeutics Inc. Board of Directors since June 2019. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Prior to joining NEA, he served as a partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons. Mr. Nunn has served on the board of directors of Trevena, Inc., a publicly-held biotechnology company focused on CNS since July 2013 and Addex Therapeutics Ltd., a publicly-held biopharmaceutical company focused on allosteric modulators for neurological disorders since June 2019 and Oventus Medical Ltd., a publicly-held medical device company since February 2020. Mr. Nunn served on the board of directors of Dermira, Inc., a publicly-held biopharmaceutical company focused on dermatology, from May 2011 until its acquisition by Eli Lilly and Company in February 2020. From 2009 to May 2015 Mr. Nunn served on the board of directors of Hyperion Therapeutics, Inc. and from 2008 to February 2016 Mr. Nunn served on the board of directors of TriVascular Technologies, Inc. Mr. Nunn received his A.B. in economics from Dartmouth College and his M.B.A. from the Stanford Graduate School of Business. He also holds the Chartered Financial Analyst designation and is a member of the CFA Society of San Francisco.
- Leon O. Moulder, Jr.
-
Leon O. Moulder, Jr.先生自2020年1月起一直担任再鼎医药有限公司的独立董事。Moulder 先生为Tellus Bio Ventures,LLC（一个处于早期阶段的生命科学投资基金）的创始普通合伙人。Moulder 先生最近曾担任Tesaro 首席执行官兼董事，自2010年共同创办该公司起一直担任该职务。Tesaro 于2019年1月被GSK（葛兰素史克公司）收购，Tesaro 是总部位于波士顿实现完全一体化专注于肿瘤学领域的生物制药公司，业务遍及北美及欧洲市场。Moulder 先生在Abraxis Bio Science,Inc.最终于2010年被Celgene Corporation 收购前曾担任该公司总裁兼首席执行官。在此之前，Moulder 先生于Eisai 收购MGI PHARMA后自2008年起担任Eisai Corporation 北美分公司副董事长，Moulder 先生自2003年开始担任MGI PHARMA总裁兼首席执行官，之前自1999年起则出任该公司执行副总裁。Moulder 先生过去曾于1997年担任一间处于创业阶段的生物科技公司的创始管理团队成员。Moulder 先生自1981年开始在Marion Laboratories（赛诺菲（Sanofi）的前身公司）任职，在该公司工作十七年后，Moulder 先生开展其临床药剂师职业生涯。Moulder 先生为天普大学（Temple University）受托人、研究受托人委员会主席、天普大学日本分校（TESS）董事会主席并担任Fox Chase Cancer Center 董事会成员。Moulder 先生为芝加哥大学布斯商学院（University of Chicago Booth School of Business）及Polsky Center for Entrepreneurship and Innovation（波尔斯基创业和创新中心）理事会成员。Moulder 先生为Helsinn Group（赫尔辛集团）董事会成员及Trevena,Inc.董事会主席，过去曾出任Cubist Pharmaceuticals 及生物技术创新组织董事会成员。Moulder 先生于1980年取得天普大学（Temple University）药学学士学位及于1997年取得芝加哥大学布斯商学院的工商管理硕士学位。
Leon O. Moulder, Jr.,Founder and Managing Member of Tellus BioVentures, LLC, a life sciences investment fund (March 2019-Present);Member of the Board of Directors of Trevena, Inc. (2011-Present), serving as Chairman since 2013;Member of the Board of Directors of the Helsinn Group (January 2020-Present);Co-Founder, Chief Executive Officer, and Member of the Board Directors of Tesaro, Inc. (NASDAQ) (May 2010-its acquisition by GSK plc in January 2019);President, Chief Executive Officer, and Vice Chairman of the Board of Directors of Abraxis BioScience, Inc. (NASDAQ) (2009- 2010);Vice Chairman of the Board of Directors of Eisai Corporation of North America, a research-based pharmaceutical company and wholly owned subsidiary of Eisai Co., Ltd. (2008-2009);President, Chief Executive Officer, and Member of the Board of Directors of MGI PHARMA, Inc. (2003-its acquisition by Eisai Corporation of North America in 2008), after serving as President and Chief Operating Officer (2002-2003) and Executive Vice President (1999-2002);Temple University Trustee (January 2013-Present), Council Member for the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation (June 2016-Present), and Board Member of the Fox Chase Cancer Center (March 2013-Present);MBA from The University of Chicago Booth School of Business and B.S. in Pharmacy from Temple University. - Leon O. Moulder, Jr.先生自2020年1月起一直担任再鼎医药有限公司的独立董事。Moulder 先生为Tellus Bio Ventures,LLC（一个处于早期阶段的生命科学投资基金）的创始普通合伙人。Moulder 先生最近曾担任Tesaro 首席执行官兼董事，自2010年共同创办该公司起一直担任该职务。Tesaro 于2019年1月被GSK（葛兰素史克公司）收购，Tesaro 是总部位于波士顿实现完全一体化专注于肿瘤学领域的生物制药公司，业务遍及北美及欧洲市场。Moulder 先生在Abraxis Bio Science,Inc.最终于2010年被Celgene Corporation 收购前曾担任该公司总裁兼首席执行官。在此之前，Moulder 先生于Eisai 收购MGI PHARMA后自2008年起担任Eisai Corporation 北美分公司副董事长，Moulder 先生自2003年开始担任MGI PHARMA总裁兼首席执行官，之前自1999年起则出任该公司执行副总裁。Moulder 先生过去曾于1997年担任一间处于创业阶段的生物科技公司的创始管理团队成员。Moulder 先生自1981年开始在Marion Laboratories（赛诺菲（Sanofi）的前身公司）任职，在该公司工作十七年后，Moulder 先生开展其临床药剂师职业生涯。Moulder 先生为天普大学（Temple University）受托人、研究受托人委员会主席、天普大学日本分校（TESS）董事会主席并担任Fox Chase Cancer Center 董事会成员。Moulder 先生为芝加哥大学布斯商学院（University of Chicago Booth School of Business）及Polsky Center for Entrepreneurship and Innovation（波尔斯基创业和创新中心）理事会成员。Moulder 先生为Helsinn Group（赫尔辛集团）董事会成员及Trevena,Inc.董事会主席，过去曾出任Cubist Pharmaceuticals 及生物技术创新组织董事会成员。Moulder 先生于1980年取得天普大学（Temple University）药学学士学位及于1997年取得芝加哥大学布斯商学院的工商管理硕士学位。
- Leon O. Moulder, Jr.,Founder and Managing Member of Tellus BioVentures, LLC, a life sciences investment fund (March 2019-Present);Member of the Board of Directors of Trevena, Inc. (2011-Present), serving as Chairman since 2013;Member of the Board of Directors of the Helsinn Group (January 2020-Present);Co-Founder, Chief Executive Officer, and Member of the Board Directors of Tesaro, Inc. (NASDAQ) (May 2010-its acquisition by GSK plc in January 2019);President, Chief Executive Officer, and Vice Chairman of the Board of Directors of Abraxis BioScience, Inc. (NASDAQ) (2009- 2010);Vice Chairman of the Board of Directors of Eisai Corporation of North America, a research-based pharmaceutical company and wholly owned subsidiary of Eisai Co., Ltd. (2008-2009);President, Chief Executive Officer, and Member of the Board of Directors of MGI PHARMA, Inc. (2003-its acquisition by Eisai Corporation of North America in 2008), after serving as President and Chief Operating Officer (2002-2003) and Executive Vice President (1999-2002);Temple University Trustee (January 2013-Present), Council Member for the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation (June 2016-Present), and Board Member of the Fox Chase Cancer Center (March 2013-Present);MBA from The University of Chicago Booth School of Business and B.S. in Pharmacy from Temple University.
- Maxine Gowen
-
Maxine Gowen，自2007年11月创立本公司以来，担任本公司的总裁和首席执行官，以及是本公司的一位董事会成员。在加入本公司之前，她曾是GlaxoSmithKline plc或GSK的外部药物发现卓越中心担任高级副总裁，在15年任期内在GlaxoSmithKline plc担任过各种领导职位。在GSK之前，她曾于2008-2012年期间，是英国（UK）Bath大学骨与关节系骨细胞生物学资深讲师和主任。2008-2012年期间，是一家公共生物医药公司- Human Genome Sciences股份有限公司的一位董事。她是从英国（UK）Sheffield大学获得她的博士学位，从宾夕法尼亚大学（University of Pennsylvania）Wharton学院获得的学术荣誉工商管理硕士学位，以及从英国（UK）Bristol大学获得的生物化学荣誉学士学位。
Maxine Gowen served as the CEO and a board director of TamuroBio Inc., a privately held drug development company, from 2019 to 2021, and she remains on the board of directors. She was the founding President and CEO of Trevena, Inc., or Trevena, (Nasdaq: TRVN), a publicly traded biopharmaceutical company, from 2007 until her retirement in 2018; she remained a member of its board of directors until 2021. Prior to joining Trevena, Dr. Gowen was Senior Vice President for the Center of Excellence for External Drug Discovery at GlaxoSmithKline plc, or GSK, where she held a variety of leadership positions during her tenure of 15 years. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, of the University of Bath, U.K. Dr. Gowen has served as a director of Aclaris Therapeutics, Inc. (Nasdaq: ACRS) since 2019, Passage Bio, Inc. (Nasdaq: PASG), and as its Chairwoman, since 2021, and Merus NV (Nasdaq: MRUS) since 2021, each a publicly traded company. She previously held a board seat in the state biotechnology industry association, Life Sciences of Pennsylvania from 2015 until 2021 and in the national biotechnology industry association, BIO, from 2008 until 2018. Dr. Gowen previously served as a director of Human Genome Sciences, Inc., from 2008 until 2012, and Akebia Therapeutics, Inc. (Nasdaq: AKBA) from 2014 until 2021, both publicly traded companies, as well as Panorama Medicine, from 2020 until 2021, a privately held biotechnology company. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K. - Maxine Gowen，自2007年11月创立本公司以来，担任本公司的总裁和首席执行官，以及是本公司的一位董事会成员。在加入本公司之前，她曾是GlaxoSmithKline plc或GSK的外部药物发现卓越中心担任高级副总裁，在15年任期内在GlaxoSmithKline plc担任过各种领导职位。在GSK之前，她曾于2008-2012年期间，是英国（UK）Bath大学骨与关节系骨细胞生物学资深讲师和主任。2008-2012年期间，是一家公共生物医药公司- Human Genome Sciences股份有限公司的一位董事。她是从英国（UK）Sheffield大学获得她的博士学位，从宾夕法尼亚大学（University of Pennsylvania）Wharton学院获得的学术荣誉工商管理硕士学位，以及从英国（UK）Bristol大学获得的生物化学荣誉学士学位。
- Maxine Gowen served as the CEO and a board director of TamuroBio Inc., a privately held drug development company, from 2019 to 2021, and she remains on the board of directors. She was the founding President and CEO of Trevena, Inc., or Trevena, (Nasdaq: TRVN), a publicly traded biopharmaceutical company, from 2007 until her retirement in 2018; she remained a member of its board of directors until 2021. Prior to joining Trevena, Dr. Gowen was Senior Vice President for the Center of Excellence for External Drug Discovery at GlaxoSmithKline plc, or GSK, where she held a variety of leadership positions during her tenure of 15 years. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, of the University of Bath, U.K. Dr. Gowen has served as a director of Aclaris Therapeutics, Inc. (Nasdaq: ACRS) since 2019, Passage Bio, Inc. (Nasdaq: PASG), and as its Chairwoman, since 2021, and Merus NV (Nasdaq: MRUS) since 2021, each a publicly traded company. She previously held a board seat in the state biotechnology industry association, Life Sciences of Pennsylvania from 2015 until 2021 and in the national biotechnology industry association, BIO, from 2008 until 2018. Dr. Gowen previously served as a director of Human Genome Sciences, Inc., from 2008 until 2012, and Akebia Therapeutics, Inc. (Nasdaq: AKBA) from 2014 until 2021, both publicly traded companies, as well as Panorama Medicine, from 2020 until 2021, a privately held biotechnology company. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.
高管简历
中英对照 | 中文 | 英文- Carrie L. Bourdow
Carrie L. Bourdow自2015年5月起担任公司高级副总裁兼首席商务官。2013年5月至2015年5月，她在Cubist Pharmaceuticals, Inc.担任营销副总裁。2013年加入Cubist之前，Bourdow女士在Merck & Co., Inc.任职20多年，在那里她在多个治疗领域担任越来越重要的职务，包括抗感染、急性心脏衰竭和疼痛。 Bourdow女士获得了Hendrix College的学士学位和 Southern Illinois University的工商管理硕士学位。
Carrie L. Bourdow has served as a member of our Board since February 2020. Ms. Bourdow has served as the President, Chief Executive Officer and a member of the board of directors of Trevena, Inc. Nasdaq: TRVN since October 2018. Prior to her role as Chief Executive Officer, Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from May 2013 until its acquisition by Merck & Co., Inc. in May 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for products totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across commercial functions and therapeutic areas. Since June 2017 she has served on the board of directors of Nabriva Therapeutics plc. (Nasdaq: NBRV), a publicly traded biopharmaceutical company.- Carrie L. Bourdow自2015年5月起担任公司高级副总裁兼首席商务官。2013年5月至2015年5月，她在Cubist Pharmaceuticals, Inc.担任营销副总裁。2013年加入Cubist之前，Bourdow女士在Merck & Co., Inc.任职20多年，在那里她在多个治疗领域担任越来越重要的职务，包括抗感染、急性心脏衰竭和疼痛。 Bourdow女士获得了Hendrix College的学士学位和 Southern Illinois University的工商管理硕士学位。
- Carrie L. Bourdow has served as a member of our Board since February 2020. Ms. Bourdow has served as the President, Chief Executive Officer and a member of the board of directors of Trevena, Inc. Nasdaq: TRVN since October 2018. Prior to her role as Chief Executive Officer, Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from May 2013 until its acquisition by Merck & Co., Inc. in May 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for products totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across commercial functions and therapeutic areas. Since June 2017 she has served on the board of directors of Nabriva Therapeutics plc. (Nasdaq: NBRV), a publicly traded biopharmaceutical company.
- Mark A Demitrack
Mark A Demitrack，获得董事会认证的精神病学家，于2018年5月加入我们公司，担任高级副总裁兼首席医疗官。2017年5月至2018年5月，他担任Roivant Sciences，Ltd.临床策略Vice President。从2003年7月至2017年5月，他担任Neuronetics，Inc.Vice President兼首席医疗官，领导Neurostar TMS治疗系统的临床开发。在此之前，Demitrack博士是惠氏制药公司（Wyeth Pharmaceuticals，Inc.）负责神经科学全球医疗事务的助理Vice President，负责Effexor XR品牌的上市后临床开发。Demitrack博士还担任礼来研究实验室（Lilly Research Laboratories）新的抗抑郁药团队的医学总监，在那里他领导了抗抑郁药度洛西汀Cymbalta的注册临床开发和NDA提交计划。在他的行业生涯之前，Demitrack博士是密歇根大学医学院（University of Michigan Medical School）精神病学系的教员，在那里他指导密歇根州饮食失调计划，并获得临床研究的联邦拨款资助，研究饮食失调的神经内分泌病理生理学和特发性条件慢性疲劳综合征和纤维肌痛。Demitrack博士在哥伦比亚大学（Columbia University）获得物理学学士学位，并在新泽西州的罗伯特·伍德·约翰逊医学院（Robert Wood Johnson Medical School）获得医学博士学位。他在University of California-San Francisco完成了精神病学住院医师培训，并在National Institute of Mental Health完成了临床神经内分泌学研究金。Demitrack博士是美国精神病学协会（American Psychological Association）的终身研究员，也是美国神经精神药理学学院（American College of Neurophychology）的成员。
Mark A Demitrack, a board-certified psychiatrist, joined our company as Senior Vice President and Chief Medical Officer in May 2018. From May 2017 to May 2018 he served as Vice President of Clinical Strategy at Roivant Sciences, Ltd. From July 2003 to May 2017 he served as Vice President and Chief Medical Officer of Neuronetics, Inc.,where he led the clinical development of the NeuroStar TMS Therapy System. Prior to this, Dr. Demitrack was Assistant Vice President for Global Medical Affairs in Neuroscience at Wyeth Pharmaceuticals, Inc. where he was responsible for post-marketing clinical development of the Effexor XR brand. Dr. Demitrack also served as Medical Director of the New Antidepressant Team at Lilly Research Laboratories where he led the registration clinical development and the NDA submission program for the antidepressant, duloxetine Cymbalta. Prior to his industry career, Dr. Demitrack was a faculty member of the Department of Psychiatry at the University of Michigan Medical School, where he directed the Michigan Eating Disorders Program and received federal grant funding in clinical research studying the neuroendocrine pathophysiology of eating disorders and the idiopathic conditions chronic fatigue syndrome and fibromyalgia. Dr. Demitrack received a B.A. in Physics from Columbia University, and his M.D. from the Robert Wood Johnson Medical School in New Jersey. He completed his psychiatry residency training at the University of California-San Francisco and completed a research fellowship in clinical neuroendocrinology at the National Institute of Mental Health. Dr. Demitrack is a Life Fellow of the American Psychiatric Association and a Member of the American College of Neuropsychopharmacology.- Mark A Demitrack，获得董事会认证的精神病学家，于2018年5月加入我们公司，担任高级副总裁兼首席医疗官。2017年5月至2018年5月，他担任Roivant Sciences，Ltd.临床策略Vice President。从2003年7月至2017年5月，他担任Neuronetics，Inc.Vice President兼首席医疗官，领导Neurostar TMS治疗系统的临床开发。在此之前，Demitrack博士是惠氏制药公司（Wyeth Pharmaceuticals，Inc.）负责神经科学全球医疗事务的助理Vice President，负责Effexor XR品牌的上市后临床开发。Demitrack博士还担任礼来研究实验室（Lilly Research Laboratories）新的抗抑郁药团队的医学总监，在那里他领导了抗抑郁药度洛西汀Cymbalta的注册临床开发和NDA提交计划。在他的行业生涯之前，Demitrack博士是密歇根大学医学院（University of Michigan Medical School）精神病学系的教员，在那里他指导密歇根州饮食失调计划，并获得临床研究的联邦拨款资助，研究饮食失调的神经内分泌病理生理学和特发性条件慢性疲劳综合征和纤维肌痛。Demitrack博士在哥伦比亚大学（Columbia University）获得物理学学士学位，并在新泽西州的罗伯特·伍德·约翰逊医学院（Robert Wood Johnson Medical School）获得医学博士学位。他在University of California-San Francisco完成了精神病学住院医师培训，并在National Institute of Mental Health完成了临床神经内分泌学研究金。Demitrack博士是美国精神病学协会（American Psychological Association）的终身研究员，也是美国神经精神药理学学院（American College of Neurophychology）的成员。
- Mark A Demitrack, a board-certified psychiatrist, joined our company as Senior Vice President and Chief Medical Officer in May 2018. From May 2017 to May 2018 he served as Vice President of Clinical Strategy at Roivant Sciences, Ltd. From July 2003 to May 2017 he served as Vice President and Chief Medical Officer of Neuronetics, Inc.,where he led the clinical development of the NeuroStar TMS Therapy System. Prior to this, Dr. Demitrack was Assistant Vice President for Global Medical Affairs in Neuroscience at Wyeth Pharmaceuticals, Inc. where he was responsible for post-marketing clinical development of the Effexor XR brand. Dr. Demitrack also served as Medical Director of the New Antidepressant Team at Lilly Research Laboratories where he led the registration clinical development and the NDA submission program for the antidepressant, duloxetine Cymbalta. Prior to his industry career, Dr. Demitrack was a faculty member of the Department of Psychiatry at the University of Michigan Medical School, where he directed the Michigan Eating Disorders Program and received federal grant funding in clinical research studying the neuroendocrine pathophysiology of eating disorders and the idiopathic conditions chronic fatigue syndrome and fibromyalgia. Dr. Demitrack received a B.A. in Physics from Columbia University, and his M.D. from the Robert Wood Johnson Medical School in New Jersey. He completed his psychiatry residency training at the University of California-San Francisco and completed a research fellowship in clinical neuroendocrinology at the National Institute of Mental Health. Dr. Demitrack is a Life Fellow of the American Psychiatric Association and a Member of the American College of Neuropsychopharmacology.
- Robert T. Yoder
RobertT.Yoder于2018年12月被任命为高级副总裁兼首席商务官。他于2018年6月加入我们公司，担任商业运营和销售Vice President。在此之前，他曾于2015年3月至2018年6月担任生物制药公司OrexigenTherapeutics，Inc.的高级副总裁兼全球商业运营，联盟管理和IT主管。在Orexigen时，Yoder先生建立了商业基础设施，专注于创新，高效和有效的业务流程和架构。此外，他领导外部业务发展工作，达成了11项合作协议，涉及67个国家。加入Orexigen公司之前，他曾任职Merck&Co.28年，在那里他曾担任多种职务，负责全球业务运营和商业功能。在其中的几个职位上，他负责大型计划的监督和执行，包括收购后的整合，并领导一系列组织设计和企业变革计划。Yoder先生在迪金森学院（Dickinson College）获得生物学学士学位，并在埃默里大学（Emory University）获得工商管理硕士学位。
Robert T. Yoder was appointed Senior Vice President and Chief Business Officer in December 2018. He joined our company as Vice President of Commercial Operations and Sales in June 2018. Prior to this, he served as Senior Vice President and Head of Global Commercial Operations, Alliance Management and IT at Orexigen Therapeutics, Inc., a biopharmaceutical company, from March 2015 through June 2018. While at Orexigen, Mr. Yoder built the commercial infrastructure with a focus on innovative, efficient, and effective business process and architecture. Additionally, he led external business development efforts that delivered 11 partnership deals spanning 67 countries. Prior to joining Orexigen, Mr. Yoder spent 28 years at Merck & Co., where he held various roles of increasing responsibility across global business operations and commercial functions. In several of these roles, he was responsible for oversight and execution of large-scale initiatives including integration following acquisitions and led a range of organizational design and corporate change initiatives. Mr. Yoder received his B.S. degree in biology from Dickinson College and earned an M.B.A. from Emory University.- RobertT.Yoder于2018年12月被任命为高级副总裁兼首席商务官。他于2018年6月加入我们公司，担任商业运营和销售Vice President。在此之前，他曾于2015年3月至2018年6月担任生物制药公司OrexigenTherapeutics，Inc.的高级副总裁兼全球商业运营，联盟管理和IT主管。在Orexigen时，Yoder先生建立了商业基础设施，专注于创新，高效和有效的业务流程和架构。此外，他领导外部业务发展工作，达成了11项合作协议，涉及67个国家。加入Orexigen公司之前，他曾任职Merck&Co.28年，在那里他曾担任多种职务，负责全球业务运营和商业功能。在其中的几个职位上，他负责大型计划的监督和执行，包括收购后的整合，并领导一系列组织设计和企业变革计划。Yoder先生在迪金森学院（Dickinson College）获得生物学学士学位，并在埃默里大学（Emory University）获得工商管理硕士学位。
- Robert T. Yoder was appointed Senior Vice President and Chief Business Officer in December 2018. He joined our company as Vice President of Commercial Operations and Sales in June 2018. Prior to this, he served as Senior Vice President and Head of Global Commercial Operations, Alliance Management and IT at Orexigen Therapeutics, Inc., a biopharmaceutical company, from March 2015 through June 2018. While at Orexigen, Mr. Yoder built the commercial infrastructure with a focus on innovative, efficient, and effective business process and architecture. Additionally, he led external business development efforts that delivered 11 partnership deals spanning 67 countries. Prior to joining Orexigen, Mr. Yoder spent 28 years at Merck & Co., where he held various roles of increasing responsibility across global business operations and commercial functions. In several of these roles, he was responsible for oversight and execution of large-scale initiatives including integration following acquisitions and led a range of organizational design and corporate change initiatives. Mr. Yoder received his B.S. degree in biology from Dickinson College and earned an M.B.A. from Emory University.
- Barry Shin
Barry Shin于2019年6月加入我们公司，担任高级副总裁兼首席财务官。他加入我们公司，拥有丰富的投资银行经验，通过融资和并购或并购交易为生物制药公司提供建议。他自2017年5月起担任瑞穗证券（Mizuho Securities）梦百合投资银行集团董事总经理，直至加入该公司。加入瑞穗证券之前，他曾于2012年5月至2017年5月担任古根海姆证券（Guggenheim Securities）梦百合投资银行集团董事总经理。从2005年2月到2012年5月，他曾任职Piper Jaffray公司的梦百合投资银行集团。从2001年9月到2005年2月，他担任公司律师，为梦百合和技术公司提供融资和并购交易方面的建议。Shin先生获得了理学学士学位。以及多伦多大学联合J.D./M.B.A.。
Barry Shin joined our company as Senior Vice President and Chief Financial Officer in June 2019. He joined our company with extensive investment banking experience advising biopharmaceutical companies through financing and merger and acquisition, or M&A, transactions. He was Managing Director in the Healthcare Investment Banking Group at Mizuho Securities from May 2017 until he joined the Company. Prior to joining Mizuho Securities, he was a Managing Director in the Healthcare Investment Banking Group of Guggenheim Securities from May 2012 to May 2017. From February 2005 to May 2012 he served in the Healthcare Investment Banking Group of Piper Jaffray. From September 2001 to February 2005 he advised healthcare and technology companies in financing and M&A transactions as a corporate attorney. Mr. Shin received a B.Sc. and joint J.D. / M.B.A. from the University of Toronto.- Barry Shin于2019年6月加入我们公司，担任高级副总裁兼首席财务官。他加入我们公司，拥有丰富的投资银行经验，通过融资和并购或并购交易为生物制药公司提供建议。他自2017年5月起担任瑞穗证券（Mizuho Securities）梦百合投资银行集团董事总经理，直至加入该公司。加入瑞穗证券之前，他曾于2012年5月至2017年5月担任古根海姆证券（Guggenheim Securities）梦百合投资银行集团董事总经理。从2005年2月到2012年5月，他曾任职Piper Jaffray公司的梦百合投资银行集团。从2001年9月到2005年2月，他担任公司律师，为梦百合和技术公司提供融资和并购交易方面的建议。Shin先生获得了理学学士学位。以及多伦多大学联合J.D./M.B.A.。
- Barry Shin joined our company as Senior Vice President and Chief Financial Officer in June 2019. He joined our company with extensive investment banking experience advising biopharmaceutical companies through financing and merger and acquisition, or M&A, transactions. He was Managing Director in the Healthcare Investment Banking Group at Mizuho Securities from May 2017 until he joined the Company. Prior to joining Mizuho Securities, he was a Managing Director in the Healthcare Investment Banking Group of Guggenheim Securities from May 2012 to May 2017. From February 2005 to May 2012 he served in the Healthcare Investment Banking Group of Piper Jaffray. From September 2001 to February 2005 he advised healthcare and technology companies in financing and M&A transactions as a corporate attorney. Mr. Shin received a B.Sc. and joint J.D. / M.B.A. from the University of Toronto.
- Scott Applebaum
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介